Trials / Completed
CompletedNCT02175186
Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Young-Hak Kim, MD, PhD · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALBIS | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-01-21
- Primary completion
- 2018-12-01
- Completion
- 2019-01-08
- First posted
- 2014-06-26
- Last updated
- 2023-03-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02175186. Inclusion in this directory is not an endorsement.